English (UK)
中文版Mr. Michael Wood
OncoMyx Therapeutics is developing potentially best-in-class (multi-armed, IV/systemically-delivered, precision medicine) oncolytic immunotherapies based upon the myxoma virus (MYXV) platform, and we have demonstrated mechanism of action and combinatorial efficacy (tumor growth inhibition) when dosed IV with various checkpoint inhibitors in multiple animal models. Our company has the industry’s most experienced oncolytic virus (OV) development team and an experienced SAB, and CEO Steve Potts was previously an executive at Ignyta (acquired by Roche for $1.7B). OncoMyx raised a $25M series A in June 2019 to advance our lead preclinical program to IND, and among our investors are BIVF (exited OV investment ViraTx for $244M at preclinical stage in 2018) and Jonathan Lim (Ignyta CEO & current Erasca CEO). On the heels of presenting our preclinical data at SITC and announcing the appointment of Mirati CEO Chuck Baum as our new Chairperson, OncoMyx is seeking a $50M+ series B/crossover to prepare for an IPO and focus on a future transition into a clinical-stage organization. Pasted below are links to our SITC posters and some recent Fierce and BioSpace articles focused on our company.
https://www.oncomyx.com/oncomyx-announces-presentation-of-preclinical-efficacy-data-of-novel-oncolytic-immunotherapy-at-sitc-2020/
https://www.fiercebiotech.com/research/arming-rabbit-pox-virus-to-fight-cancer
https://www.biospace.com/article/oncomyx-s-oncolytic-virus-platform-shows-preclinical-efficacy-boosting-immunotherapy-potential/
OncoMyx Therapeutics
Cofounder, COO & CFOWei Wu
Illumina Ventures
InvestorDr. jun xia
ACL is a bio-pharmaceutical and medical device company with patented (US & China) technologies and products.
We have achieved our first goal via BrainGlucoseTM by providing timed release of brain energy as circadian therapy to eliminate nightmares, night sweating, hallucinations, which have been saving lives and dignity of many early and mid-stage Alzheimer’s patients; and to help diabetics to avoid nocturnal hypoglycemia for better sleep and protection from seizures, coma or even death.
More excitingly, through communications with FDA and experts in biopharmaceutical fields, we are initiating for phase III clinical study inquiry for our delayed and sustained release of energy product as breakthrough new drug status for Alzheimer’s disease.
We are also looking for investment or partnership to advance our game changing technology product, a noninvasive medical device, AddMemTM, which will be also the world’s first ever product for memory consolidation and recovery.
ACL is also a licensed manufacturer for medical food in Pennsylvania.
Our product can be marketed in China through registration with Chinese FDA as “special medical formulated food”, or apply as a new drug.
able cerebral, llc
Co-Founder / Presidentzuyong Xia
Theramix
ceoDr. Xing Xing
YDS is endeavoring to decrease the cost of drug discovery, especially in the lead discovery and optimization stages. To decrease such trial-and-error costs at these stages, YDS shifts the knowledge-based process to a self-learning process. The AI+biophysics system developed at YDS is able to optimize chemical molecules towards desired biophysical/chemical properties, serving as GPS for the drug discovery journey.
YDS Medicine, Inc.
CEODr. Chuanbo Xu
Freenome, Inc.
Senior Director, Clinical DevelopmentJohn Xu
We have a very unique T-cell engager Bi-specific antibody platform.
Our COVID-19 neutralization antibody project is in phae 2 clinical tiral.
We have about 10 different Bi-specific projects in pre-clinical stage focusing on oncology, autoimmune and ophthomology.
We are looking for China partners to codevelop the Bi-specific antibodies.
We are also raising the capital to set up the CHina subsidiary.
You can add my wechat: elite8800
Responsive Web Design powered by 